Investors
ConjuChem Investor Information
The Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™) technology platforms created by ConjuChem have very broad applicability. The Company has identified and investigated a large number of small organic molecules and therapeutic peptides it believes could be used to form new constructs with attractive market potential.
Management's Discussion and Analysis
of
Financial Condition and Results of Operations
© 1999-2007, ConjuChem, Inc. All rights reserved.
